Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Head and neck carcinomas
kynurenine
plasma galectins
plasma metabolites
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Extra-cellular galectins 1, 3 and 9 (gal-1, -3 and -9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of producing cells and reciprocally that they can influence metabolic pathways in their target cells. Very little is known about the status of gal-1, -3 and -9 in patients bearing head and neck squamous cell carcinomas (HNSCC) and about their relationships with the systemic metabolic condition. This study was conducted in plasma samples from a prospective cohort of 83 HNSCC patients with advanced disease. These samples were used to explore the distribution of gal-1, -3 and -9 and simultaneously to profile a series of 87 metabolites assessed by mass spectrometry. We identified galectin and metabolic patterns within five disease categories defined according to the primary site and human papillomavirus (HPV) status (HPV-positive and -negative oropharyngeal carcinomas, carcinomas of the oral cavity, hypopharynx and larynx carcinomas). Remarkably, samples related to hypopharyngeal carcinomas displayed the highest average concentration of gal-9 (
Identifiants
pubmed: 36545254
doi: 10.1080/2162402X.2022.2150472
pii: 2150472
pmc: PMC9762837
doi:
Substances chimiques
1-nitrohydroxyphenyl-N-benzoylalanine
59921-69-6
Galectins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2150472Informations de copyright
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
PB and MD are members of a collaborative project on monoclonal antibodies neutralizing extra-cellular gal-9. This project involves P. Busson’s team and HiFIBiO-Therapeutics. Otherwise, the authors declare no potential conflicts of interest.
Références
Cell Death Dis. 2021 Jul 21;12(8):725
pubmed: 34290225
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287347
J Clin Invest. 2019 Dec 2;129(12):5553-5567
pubmed: 31710313
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Am Heart Assoc. 2018 Nov 6;7(21):e009098
pubmed: 30571380
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Semin Cell Dev Biol. 2018 Nov;83:42-50
pubmed: 29501720
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389859
Oral Oncol. 2008 Jan;44(1):86-93
pubmed: 17350328
Adv Cancer Res. 2021;152:67-102
pubmed: 34353444
Nat Rev Rheumatol. 2021 Nov;17(11):678-691
pubmed: 34611329
Immunol Rev. 2009 Jul;230(1):160-71
pubmed: 19594635
J Pers Med. 2021 Jul 10;11(7):
pubmed: 34357118
J Immunol. 2017 Dec 1;199(11):3721-3730
pubmed: 29158348
Oncoimmunology. 2019 Jan 22;8(4):e1564505
pubmed: 30906658
Curr Oncol. 2020 Jun;27(3):135-141
pubmed: 32669922
Oncogenesis. 2020 Jul 6;9(7):65
pubmed: 32632113
Aging (Albany NY). 2019 Jul 24;11(14):4783-4800
pubmed: 31346149
Nat Commun. 2017 Oct 6;8(1):793
pubmed: 28986561
Oncotarget. 2018 Aug 31;9(68):32984-32996
pubmed: 30250644
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
J Immunol. 2010 Aug 1;185(3):1383-92
pubmed: 20574007
Biochem Pharmacol. 2020 Aug;178:114113
pubmed: 32579956
J Intern Med. 2020 Feb;287(2):134-152
pubmed: 31733108
PLoS One. 2015 Jul 29;10(7):e0134458
pubmed: 26222311
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Exp Gerontol. 2020 Apr;132:110841
pubmed: 31954874
Am J Surg. 1987 Oct;154(4):439-42
pubmed: 3661849
Nat Commun. 2020 Aug 11;11(1):4011
pubmed: 32782249
Laryngoscope. 2001 Jul;111(7):1297-301
pubmed: 11568558
Oral Oncol. 2018 Nov;86:244-250
pubmed: 30409307
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Sci Rep. 2021 Aug 9;11(1):16134
pubmed: 34373557
Int J Rheum Dis. 2019 Oct;22(10):1820-1824
pubmed: 31402566
Cell Mol Immunol. 2018 May;15(5):447-457
pubmed: 29375124
Head Neck Pathol. 2021 Mar;15(1):163-168
pubmed: 32564273
Clin Cancer Res. 2020 Dec 1;26(23):6086-6101
pubmed: 32709716
Eur J Pharmacol. 2021 Jan 5;890:173637
pubmed: 33065093
Pathol Oncol Res. 1998;4(1):14-21
pubmed: 9555115
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Cancer Res. 2019 Mar 15;79(6):1138-1150
pubmed: 30679179
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Acta Oncol. 2021 Nov;60(11):1534-1542
pubmed: 34410881
Arthritis Rheumatol. 2014 Aug;66(8):2281-9
pubmed: 24756983
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967162
Bratisl Lek Listy. 2021;122(9):60-617
pubmed: 34463104
J Biosci Bioeng. 2014 Jan;117(1):122-8
pubmed: 23867096
Cardiovasc Diabetol. 2015 Jun 06;14:73
pubmed: 26047815
Cancer Res. 2002 May 1;62(9):2493-7
pubmed: 11980639
Blood. 2009 Feb 26;113(9):1957-66
pubmed: 19005181